INO — +224% premarket as FDA approves Voceryq, first plasmid DNA immunotherapy

Inovio surged about 224% premarket after the FDA granted accelerated approval to Voceryq (INO-3107), its DNA-based immunotherapy to reduce surgery frequency in adults with recurrent respiratory papillomatosis — reportedly the first plasmid DNA immunotherapy the agency has approved. The decision landed on the Oct. 30 PDUFA date after the stock slid 22% in Friday's session; shares had already more than tripled in after-hours trading.